Mergers & acquisitions
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion.
Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza’s Water Care business and operations for USD 630 million.
Nestlé Increases Stake in Aimmune as Company Eyes Filing for FDA Approval of Peanut Allergy Medicine
As California-based Aimmune prepares to seek regulatory approval for its peanut allergy treatment, AR101, Nestlé Health Science has increased its financial stake in the food allergy prevention-focused company with another $98 million investment.
Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.
Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies
Shares of Asterias Biotherapeutics have soared nearly 30 percent in premarket trading after it was announced that the Fremont, Calif.-based company was being absorbed by BioTime, Inc. in an attempt to create a leading cell therapy company.
AstraZeneca is unloading rights to Alvesco (ciclesonide) to treat persistent asthma, and Omnaris and Zetonna (ciclesonide) to treat nasal symptoms associated with rhinitis. The company indicates that the rights cover markets outside the United States and the U.S. royalties for the drugs.
The deal to acquire its rival, Pacific Biosciences, will provide Illumina with a more comprehensive sequencing test at a lower cost.
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
As the acquisition of Shire by Takeda Pharmaceutical inches forward, global regulatory agencies are signing off on the deal. As the European Commission (EC) conducts a review of the deal, it hit a snag.
PRESS RELEASES